By stimulating cells with recombinant WNT5A (rWNT5A), the authors demonstrated that resistance to BRAFi (i.e., PLX4720) increased two-fold in the BRAFi sensitive melanoma cell line 451 LU. This evidence concerns the gene WNT5A and melanoma.